Extracellular tumor DNA in plasma and overall survival in breast cancer patients

Genes Chromosomes and Cancer

Volumn 45, Issue 7, 2006, Pages 692-701

  Garcia, Jose N ^a   Garcia, Vanesa ^a   Silva, Javier ^a   Peña, Cristina ^a   Dominguez, Gemma ^a   Sanchez, Antonio ^a   Sanfrutos, Luis ^b   Provencio, Mariano ^a   Millan, Isabel ^a   Chaparro, Dolores ^a   España, Pilar ^a   Bonilla, Felix ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA DETERMINATION; DNA EXTRACTION; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MARKER GENE; PRIORITY JOURNAL; PROGNOSIS; TP53 GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33646554854     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20334     Document Type: Article

References (61)

1. Anker P, Lefort F, Vasioukhin V, Lyautey J, Lederrey C, Chen XQ, Stroun M, Mulcahy HE, Farthing MJ. 1997. K-ras gene mutations in the plasma of colorectal cancer patients. Gastroenterology 112:1114-1120.
2. Armitage P, Berry G. 1987. Statistical Methods in Medical Research. Oxford: Blackwell.
3. Au WY, Pang A, Choy C, Chim CS, Kwong YL. 2004. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104:243-249.
4. Caponigro F, Iaffaioli RV, Pagliarulo C, De Placido S, Frasci G, Ungaro B, Matano E, Bianco AR. 1990. CA 15-3 in human breast cancer. Comparison wich tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Int J Biol Markers 5:73-76.
5. Castells A, Puig P, Mora J, Boadas J, Boix L, Urgell E, Sole M, Capella G, Lluis F, Fernandez-Cruz L, Navarro S, Farre A. 1999. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: Diagnostic utility and prognostic significance. J Clin Oncol 17:578-584.
6. Chang HW, Lee SM, Goodman SN, Singer G, Cho SK, Sokoll LJ, Montz FJ, Roden R, Zhang Z, Chan DW, Kurman RJ, Shih IeM. 2002. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst 94:1697-1703.
7. Chen X, Bonnefoi H, Diebold-Berger S, Lyautey J, Lederrey C, Faltin-Traub E, Stroun M, Anker P. 1999. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 5:2297-2303.
8. Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P. 1996. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 2:1033-1035.
9. Coulet F, Blons H, Cabelguenne A, Lecomte T, Lacourreye O, Brasnu D, Beaune P, Zucman J, Laurent-Puig P. 2000. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatrellite typing and p53 mutation analysis. Cancer Res 60:707-711.
10. Cox DR. 1972. Regression models and life tables. J Royal Stat Soc Series B 34:187-202.
11. Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA. 1997. p53 mutations in BRCA1-associated familial breast cancer. Lancet 350:638-639.
12. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. 1996. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274:2057-2059.
13. Dominguez G, Carballido J, Silva J, Silva JM, Garcia JM, Menendez J, Provencio M, Espana P, Bonilla F. 2002. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 8:980-985.
14. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717.
15. Esteller M, Sánchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. 1999. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59:67-70.
16. Frickhofen N, Muller E, Sandherr M, Binder T, Bangerter M, Wiest C, Enz M, Heimpel H. 1997. Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia. Blood 90:4953-4960.
17. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chasse E, Ratschiller D, Weder W, Joerger M, Betticher DC, Stahel RA, Ziegler A. 2004. Circulating deoxyribonucleic acid as prognostic marker in non small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 22:4157-4164.
18. Goessl C, Heicappell R, Munker R, Anker P, Stroun M, Krause H, Muller M, Miller K. 1998. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. Cancer Res 58:4728-4732.
19. Gonzalez R, Silva JM, Sanchez A, Dominguez G, Garcia JM, Chen XQ, Stroun M, Provencio M, Espana P, Anker P, Bonilla F. 2000. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: Follow-up study and prognostic significance. Ann Oncol 11:1097-1104.
20. Greenlee RT, Murray T, Bolden S, Wingo PA. 2000. Cancer statistics, 2000. CA Cancer J Clin 50:7-33.
21. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JR Davidson NE, Sidransky D, Baylin SB. 1995. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530.
22. Herrera LJ, Raja S, Gooding WE, El-Hefnawy T, Kelly L, Luketich JD, Godfrey TE. 2004. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 5:113-118.
23. Hibi K, Robinson CR, Booker S, Wu L, Hamilton SR, Sidransky D, Jen J. 1998. Molecular detection of genetics alterations in serum of colorectal cancer patients. Cancer Res 58:1405-1407.
24. Ibanez de Caceres I, Battagli C, Esteller M, Hermen JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL, Cairns P. 2004. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 64:6476-6481.
25. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. 2001. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659-1665.
26. Kaplan EL, Meier P. 1958. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
27. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT Demeester TR, Eads C, Laird PW, Ilson DH, Kelsen DP, Harpole D, Moore MB, Danenberg KD, Danenberg PV, Meltzer SJ. 2000. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 92:1805-1811.
28. Kondo H, Sugano K, Fukayama N, Kyogoku A, Nose H, Shimada K, Ohkura H, Ohtsu A, Yoshida S, Shimosato Y. 1994. Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 73:1589-1594.
29. Kumar R, Sukumar S, Barbacid M. 1990. Activation of ras oncogenes preceding the onset of neoplasia. Science 248:1101-1104.
30. Leitch AM, Dodd GD, Costanza M, Linver M, Pressman P, Mc-Ginnis L, Smith RA. 1997. American Cancer Society guidelines for the early detection of breast cancer. CA Cancer J Clin 47:150-153.
31. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. 1977. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646-650.
32. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS. 2004. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350:2461-2479.
33. Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, Lee JC, Hjelm NM, Johnson PJ, Huang DP. 1999a. Quantitative and temporal correlation between circulating cell-free-Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 59:5452-5455.
34. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP. 1999b. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinomas. Cancer Res 59:1188-1191.
35. Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D. 1994. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 54:1634-1637.
36. Motomura K, Koyama H, Noguchi S, Inaji H, Azuma C. 1995. Detection of c-erbB-2 gene amplification in nipple discharge by means of polymerase chain reaction. Breast Cancer Res Treat 33:89-92.
37. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. 1996. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 2:1035-1037.
38. Patel U, Grundfest-Broniatowski S, Gupta M, Banerjee S. 1994. Microsatellite instabilities at five chromosomes in primary breast tumors. Oncogene 9:3695-3700.
39. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. 1997. Design and analysis of randomized clinical trials requiring prolonged observations of each patients. II. Analysis and examples. Br J Cancer 35:1-39.
40. Phelan CM, Borg A, Cuny M, Crichton DN, Baldersson T, Andersen TI, Caligo MA, Lidereau R, Lindblom A, Seitz S, Kelsell D, Hamann U, Rio P, Thorlacius S, Papp J, Olah E, Ponder B, Bignon YJ, Scherneck S, Barkardottir R, Borresen-Dale AL, Eyfjord J, Theillet C, Thompson AM, Larsson C. 1998. Consortium study on 1280 breast carcinomas: Allelic loss on chromosome 17 target subregions associated with family history and clinical parameters. Cancer Res 58:1004-1012.
41. Sanchez-Cespedes M, Monzo M, Rosell R, Pifarre A, Calvo R, Lopez-Cabrerizo MP, Astudillo J. 1998. Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann Oncol 9:113-116.
42. Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, Coebergh JW, Colonna M, Crosignani P, Danzon A, Federico M, Gafa L, Grosclaude R Hedelin G, Mace-Lesech J, Garcia CM, Moller H, Paci E, Raverdy N, Tretarre B, Williams EM; European Concerted Action on Survival and Care of Cancer Patients (EUROCARE) Working Group. 2004. Breast carcinoma survival in Europe and the United States. Cancer 100:715-722.
43. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. 1983. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51:2116-2120.
44. Shaw JA, Smith BM, Walsh T, Johnson S, Primrose L, Slade MJ, Walker RA, Coombes RC. 2000. Microsatellite alterations in plasma DNA of primary breast cancer patients. Clin Cancer Res 6:1119-1124.
45. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P. 1991. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706-709.
46. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P. 1992. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256:102-105.
47. Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F, Provencio M, San Martin S, Espana P, Bonilla F. 1999a. Presence of tumor DNA in plasma of breast cancer patients: Clinicopathological correlations. Cancer Res 59:3251-3256.
48. Silva JM, Gonzalez R, Provencio M, Dominguez G, Garcia JM, Gallego I, Palacios J, España P, Bonilla F. 1999b. Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer. Breast Cancer Res Treat 53:9-17.
49. Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, Sanfrutos L, Jareno E, Colas A, Espana P, Bonilla F 2002. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res 8:3761-3766.
50. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J. 1996. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:173-182.
51. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U. 2003. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21:3902-3908.
52. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA, Tavecchio L. 2001. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 61:4675-4678.
53. Taback B, Fujiwara Y, Wang HJ, Foshag LJ, Morton DL, Hoon DS. 2001. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res 61:5723-5726.
54. Taback B, O'Day SJ, Boasberg PD, Shu S, Fournier P, Elashoff R, Wang HJ, Hoon DS. 2004. Circulating DNA microsatellites: Molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst 96:152-156.
55. Thijssen MA, Swinkels DW, Ruers TJ, de Kok JB. 2002. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res 22:421-425.
56. To EW, Chan KC, Leung SF, Chan LY, To KF, Chan AT, Johnson PJ, Lo YM. 2003. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 9:3254-3259.
57. Toyama T, Iwase H, Yamashita H, Iwata H, Yamashita T, Ito K, Hara Y, Suchi M, Kato T, Nakamura T, Kobayashi S. 1996. Microsatellite instability in sporadic human breast cancer. Int J Cancer 68:447-451.
58. Utting M, Werner W, Dahse R, Schubert J, Junker K. 2002. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: A minimally invasive method for the detection of bladder cancer. Clin Cancer Res 8:35-40.
59. Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. 1994. Point mutation of the N-ras gene in the blood plasma DNA of patients with Myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 86:774-779.
60. Weinberg RA. 1991. Tumor suppressor genes. Science 254:1138-1146.
61. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM, Johnson PJ. 1999. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59:71-73.